The GIPC1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt GIPC1 gene function in the human B lymphocyte cell line Raji. This product provides a genetically heterogeneous loss-of-function model, enabling the study of GIPC1-dependent mechanisms without clonal selection. The knockout is achieved through CRISPR/Cas9-mediated gene disruption, generating a pool of cells with diverse editing events that collectively ablate functional GIPC1 expression. This approach preserves the intrinsic variability of a polyclonal background, facilitating robust assessment of GIPC1??s role in cellular processes while minimizing clonal artifacts.
Derived from an Epstein-Barr virus (EBV)-positive lymphoblastoid cell line from a Burkitt??s lymphoma patient, the Raji host cells are a well-established model of B lymphocyte biology. They retain key characteristics of the adaptive immune system, including active antibody production and surface receptor signaling. The EBV transformation sustains continuous proliferation, making Raji cells highly amenable to genetic manipulation and functional assays. Their lymphoblastoid nature permits investigation of B-cell receptor trafficking, endocytosis, and adhesion, which are central to both normal immune function and lymphomagenesis.
GIPC1 encodes a PDZ domain-containing scaffold protein that orchestrates endocytic trafficking, receptor signaling, and cytoskeletal dynamics. It directly interacts with transmembrane receptors such as IGF1R, integrin alpha5/beta1, neuropilin-1, and TrkA, coupling them to downstream effectors. Through its PDZ domain, GIPC1 recruits APPL1 and myosin VI to regulate IGF1R-APPL1-AKT signaling and integrin recycling, respectively. Upstream activation by ligands including IGF-1, VEGF, TGF-beta, PDGF, and semaphorin 3A triggers GIPC1??s scaffolding function, leading to AKT phosphorylation, ERK pathway activation, and RhoA-mediated cytoskeletal rearrangements. Additionally, GIPC1 facilitates kinesin light chain-dependent transport and endosomal trafficking, influencing surface expression of integrins and other receptors. Disruption of GIPC1 therefore uncouples these receptors from their downstream signaling and trafficking pathways.
In the Raji B lymphocyte context, GIPC1 loss profoundly impacts processes critical for lymphoid cell function and transformation. The knockout impairs PDZ-mediated scaffolding of receptor complexes, disrupting endocytic recycling and attenuating AKT and ERK cascades. This alters B-cell receptor surface dynamics, integrin-mediated adhesion, and migratory capacity??all pathways implicated in lymphoma progression. By abolishing GIPC1-dependent trafficking and signaling, this model enables precise dissection of how scaffold proteins coordinate receptor crosstalk in immune cells and reveals vulnerabilities that may be exploited in B-cell malignancies.
This polyclonal knockout cell pool is suited for diverse experimental applications. Researchers can employ Western blotting and RT-qPCR to confirm GIPC1 ablation and monitor downstream targets like phosphorylated AKT and ERK. Immunofluorescence and flow cytometry allow visualization of integrin localization and surface receptor changes. Co-immunoprecipitation assays assess disrupted GIPC1 interactions with IGF1R or neuropilin-1. Functional studies??including migration and invasion assays, as well as endocytosis/recycling assays using labeled ligands??quantify the phenotypic consequences of GIPC1 loss. These cells support screening for GIPC1-dependent drug targets and mechanistic studies in cancer, cardiovascular, and neurological disease contexts. For further details, contact Ascent Research.
